Significant antitumor activity of cationic multilamellar liposomes containing human interferon-β gene in combination with 5-fluorouracil against human renal cell carcinoma

International Journal of Oncology

Volumn 33, Issue 3, 2008, Pages 565-571

  Yamamoto, Kosuke ^a   Mizutani, Yoichi ^a   Nakanishi, Hiroyuki ^a   Fujiwara, Jun ^a   Ishida, Hirokazu ^a   Toiyama, Daisuke ^a   Abe, Koichi ^a   Hayashi, Issei ^a   Okada, Koichi ^a   Kawauchi, Akihiro ^a   Mizuno, Masaaki ^b   Yoshida, Jun ^b   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Cationic multimellar liposome containing human interferon gene; Gene therapy; Renal cell carcinoma

Indexed keywords

BETA INTERFERON; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; FLOXURIDINE PHOSPHATE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LIPOSOME; OROTATE PHOSPHORIBOSYLTRANSFERASE; PACLITAXEL; TETRAZOLIUM; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CATION; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; COLORIMETRY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; DRUG TRANSFORMATION; ENZYME ACTIVITY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; KIDNEY CARCINOMA; METASTASIS POTENTIAL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; THIN LAYER CHROMATOGRAPHY; UPREGULATION; ANIMAL; DRUG EFFECT; DRUG SCREENING; GENETICS; IMMUNOTHERAPY; KIDNEY TUMOR; METABOLISM; METHODOLOGY; MOUSE MUTANT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, RENAL CELL; CATIONS; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INTERFERON-BETA; KIDNEY NEOPLASMS; LIPOSOMES; MICE; MICE, SCID; PACLITAXEL; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54849186300     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000041     Document Type: Article

References (30)

1. Miyake H, Hara I, Sakai I, et al: Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report. Int J Clin Oncol 10: 338-341, 2005.
2. Alatrash G, Hutson TE, Molto L, et al: Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22: 2891-2900, 2004.
3. Rinehart JJ, Young D, Laforge J, Colburn D and Neidhart J: Phase I/II trial of recombinant gamma-interferon in patients with renal cell carcinoma: immunologic and biologic effects. J Biol Response Mod 6: 302-312, 1987.
4. Atzpodien J, Kirchner H, Illiger HJ, et al: IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85: 1130-1136, 2001.
5. Dutcher JP, Logan T, Gordon M, et al: Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 6: 3442-3450, 2000.
6. Kawai K, Tani K, Yamashita N, et al: Advanced renal cell carcinoma treated with granulocyte-macrophage colony-stimulating factor gene therapy: a clinical course of the first Japanese experience. Int J Urol 9: 462-466, 2002.
7. Berns AJ, Clift S, Cohen LK, et al: Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 6: 347-368, 1995.
8. Schmidt-Wolf IG, Finke S, Trojaneck B, et al: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81: 1009-1016, 1999.
9. Galanis E, Hersh EM, Stopeck AT, et al: Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 17: 3313-3323, 1999.
10. Nakanishi H, Mizutani Y, Kawauchi A, et al: Significant anti-tumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma. Clin Cancer Res 9: 1129-1135, 2003.
11. Matsubara H, Mizutani Y, Hongo F, et al: Gene therapy with TRAIL against renal cell carcinoma. Mol Cancer Ther 5: 2165-2171, 2006.
12. Natsume A, Tsujimura. K, Mizuno M, Takahashi T and Yoshida J: IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. J Neurooncol 47: 117-124, 2000.
13. Aoki H, Mizuno M, Natsume A, et al: Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50: 463-468, 2001.
14. Tana, Watarai S, Lee JT, et al: In vivo antitumor effect of cationic liposomes containing diphtheria toxin A-chain gene on cells infected with bovine leukemia virus. J Vet Med Sci 59: 617-619, 1997.
15. Zhao DD, Watarai S, Lee JT, Kouchi S, Ohmori H and Yasuda T: Gene transfection by cationic liposomes: comparison of the transfection efficiency of liposomes prepared from various positively charged lipids. Acta Med Okayama 51: 149-154, 1997.
16. Arima H, Aramaki Y and Tsuchiya S: Effects of oligodeoxy-nucleotides on the physicochemical characteristics and cellular uptake of liposomes. J Pharm Sci 86: 438-442, 1997.
17. Lee JT, Watarai S, Kakidani H, Onuma M, Zhao DD and Yasuda T: Evaluation of cationic liposomes for delivery of diphtheria toxin A-chain gene to cells infected with bovine leukemia virus. J Vet Med Sci 59: 169-174, 1997.
18. Matsuoka M, Wispriyono B and Igisu H: Increased cytotoxicity of cadmium in fibroblasts lacking c-fos. Biochem Pharmacol 59: 1573-1576, 2000.
19. Foekens JA, Romain S, Look MP, Martin PM and Klijn JG: Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61: 1421-1425, 2001.
20. Spears CP, Shahinian AH, Moran RG, Heidelberger C and Corbett TH: In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42: 450-456, 1982.
21. Mizutani Y, Wada H, Ogawa O, et al: Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 92: 510-518,2001.
22. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakanishi H and Miki T: Significance of orotate phosphoribosyltransferase activity in renal cell carcinoma. J Urol 171: 605-610, 2004.
23. Massacesi C, Burattini L, Marcucci F and Bonsignori M: Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma. J Interferon Cytokine Res 25: 165-168, 2005.
24. Samland D, Steinbach F, Reiher F, Schmidt U, Gruss A and Allhoff EP: Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer. Eur Urol 35: 204-209, 1999.
25. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M and Poliwoda H: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29A: S6-S8, 1993.
26. Lopez Hanninen E, Kirchner H and Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25, 1996.
27. Atzpodien J, Kirchner H, Duensing S, et al: Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 13: 174-177, 1995.
28. Kase S, Kubota T, Watanabe M, Teramoto T, Kitajima M and Hoffman RM: Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissue. Anticancer Res 14: 1155-1159, 1994.
29. Tsunoo H, Komura S, Ohishi N, et al: Effect of transfection with human interferon-beta gene entrapped in cationic multi-lamellar liposomes in combination with 5-fluorouracil on the growth of human esophageal cancer cells in vitro. Anticancer Res 22: 1537-1543, 2002.
30. Choi EA, Lei H, Maron DJ, et al: Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. Clin Cancer Res 10: 1535-1544, 2004.